References
- Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
- Wright G, Tan B, Rosenwald A, Hurt E H, Wiestner A, Staudt L M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996
- Lenz G, Wright G W, Emre N CT, Kohlhammer H, Dave S S, Davis R E, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520–13525
- Habermann T M, Wang S S, Maurer M J, Morton L M, Lynch C F, Ansell S M, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008; 112: 2694–2702
- Houldsworth J, Petlakh M, Olshen A B, Chaganti R. Pathway activation in large B-cell non-Hodgkin's lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response. Leuk Lymphoma, 2008;49:2170–2180
- Young K H, Weisenburger D D, Dave B J, Smith L, Sanger W, Iqbal J, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007; 110: 4396–4405
- Zainuddin N, Berglund M, Wanders A, Ren Z P, Amini R M, Lindell M, et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res, in press
- Lam L T, Davis R E, Wright G, Rosenwald A, Hurt E M, Xu Y, et al. Small molecule inhibitors of IkB-kinase are selectively toxic for subgroups of diffuse large b cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28–40
- Linderoth J, Edén P, Ehinger M, Valcich J, Jerkeman M, Bendahl P O, et al. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 423–432
- Bracht K, Kiefer T, Dölken G, Bednarski P J. Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status. J Cancer Res Clin Oncol 2007; 133: 957–967
- Wilson K S, Sehn L H, Berry B, Chhanabhai M, Fitzgerald C A, Gill K K, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 1102–1109
- Liu Y Y, Leboeuf C, Shi J Y, Li J M, Wang L, Shen Y, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood 2007; 110: 339–344